ArticleFrontiers in pharmacology2025
Impact of lymphocyte transformation test on the diagnostic accuracy of the culprit drug in drug-induced cytopenias: a case-control study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-induced cytopenias are serious adverse drug reactions (ADRs), often challenging to diagnose. While causality algorithms offer high sensitivity and positive predictive values, they exhibit low specificity and negative predictive values for identifying the causative drug(s). Therefore, complementary diagnostic tools are required. Objective: This study aimed to evaluate the utility of the lymphocyte transformation test (LTT) in supporting the causality assessment of the Spanish Pharmacovigilance System (SPS) causality algorithm in the diagnosis of the implicated drug(s) in drug-induced cytopenias, using a sample of 40 cases and 85 controls. Methods: Suspected cytopenia cases were identified through the Proactive Pharmacovigilance Program for Laboratory Signals in Hospital or via pharmacovigilance consultation. Control patients completed their treatment without experiencing any ADR. A receiver-operating characteristic (ROC) curve analysis was performed to determine the optimal stimulation index (SI) cut-off for the LTT, maximizing the sum of specificity and sensitivity values to accurate identify cytopenias cases. Results: The case group included 29 cases (72.5%) of agranulocytosis, 6 (15.0%) of neutropenia, 2 (5.0%) of haemolytic anaemia, 2 (5.0%) of bicytopenia and 1 (2.5%) of bone marrow aplasia in 39 patients. Most had ≥3 comorbidities (66.7%) and no previous allergies (71.8%). Eighty-four drugs were suspected as causative agents (SPS-score ≥+4), with metamizole being the most frequent (17.2%), followed by acetaminophen (9.1%) and amoxicillin-clavulanate (8.1%). Eight cases (20.0%) involved a single suspected drug, while two cases (5.0%) involved polypharmacy (≥5 drugs). LTT was positive in 75% of cases and in 1.2% of controls. Forty one (41.4%) of the 99 suspected drugs yielded positive LTT result. With an optimal SI cut-off of 1.95, the LTT achieved a sensitivity of 72% and a specificity of 99% (area under the curve, 0.86; 95% CI 0.77-0.96; Conclusion: This study demonstrates that the LTT can be a valuable tool for strengthening causality assessment in suspected drug-induced cytopenias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.